64 citations
Counting papers with at most 25 authors, so collaboration author lists do not stand in for the people here.
- University of MichiganUS5 papers
- Eli Lilly (United States)US3 papers
- AbbVie (Japan)1 paper
- Amgen (United States)US1 paper
- Berkeley CollegeUS1 paper
- Boston UniversityUS1 paper
- Bristol-Myers Squibb (United States)US1 paper
- CSL (Switzerland)CH1 paper
- CSL (United States)US1 paper
- Day Kimball HealthcareUS1 paper
- Eli Lilly (Canada)CA1 paper
- Eli Lilly (Singapore)SG1 paper
4 papers · 1 filter
Biomedical Knowledge Graph Refinement and Completion using Graph Representation Learning and Top-K Similarity Measure
Islam Akef Ebeid, Majdi Hassan, Tingyi Wanyan +3
Knowledge Graphs have been one of the fundamental methods for integrating heterogeneous data sources. Integrating heterogeneous data sources is crucial, especially in the biomedica…
Deep Historical Borrowing Framework to Prospectively and Simultaneously Synthesize Control Information in Confirmatory Clinical Trials with Multiple Endpoints
Tianyu Zhan, Yiwang Zhou, Ziqian Geng +5
In current clinical trial development, historical information is receiving more attention as it provides utility beyond sample size calculation. Meta-analytic-predictive (MAP) prio…
Clinical Trial Drug Safety Assessment for Studies and Submissions Impacted by COVID-19
Mary Nilsson, Brenda Crowe, Greg Anglin +4
In this paper, we provide guidance on how standard safety analyses and reporting of clinical trial safety data may need to be modified, given the potential impact of the COVID-19 p…
A practical Response Adaptive Block Randomization (RABR) design with analytic type I error protection
Tianyu Zhan, Lu Cui, Ziqian Geng +3
Response adaptive randomization (RAR) is appealing from methodological, ethical, and pragmatic perspectives in the sense that subjects are more likely to be randomized to better pe…